Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma
暂无分享,去创建一个
Pietro Mancosu | Luca Cozzi | Giacomo Reggiori | Antonella Stravato | Francesca Lobefalo | Stefano Tomatis | Antonella Fogliata | Martina Sollini | Margarita Kirienko | Arturo Chiti | Davide Franceschini | Marta Scorsetti | Ciro Franzese | M. Scorsetti | P. Mancosu | L. Cozzi | A. Fogliata | F. Lobefalo | G. Reggiori | A. Tozzi | A. Stravato | A. Chiti | M. Sollini | S. Tomatis | M. Kirienko | C. Franzese | D. Franceschini | A. Zerbi | Elena Clerici | Angelo Tozzi | T. Comito | Alessandro Zerbi | Tiziana Comito | L. Di Brina | Cristiana Bonifacio | Lucia Di Brina | C. Bonifacio | E. Clerici
[1] L. Cozzi,et al. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[2] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[3] Tara Kent,et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. , 2011, International journal of radiation oncology, biology, physics.
[4] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[5] Paolo Francescon,et al. Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration , 2010, Annals of Surgical Oncology.
[6] B. Erickson,et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study , 2017, PloS one.
[7] Richard Tuli,et al. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. , 2017, Journal of gastrointestinal oncology.
[8] Irène Buvat,et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. , 2018, Cancer research.
[9] Masoom A. Haider,et al. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma – a quantitative analysis , 2017, BMC Medical Imaging.
[10] Daniel Normolle,et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. , 2012, International journal of radiation oncology, biology, physics.
[11] L Cozzi,et al. PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology , 2017, Scientific Reports.
[12] L. Cozzi,et al. [18F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results , 2017, European Journal of Hybrid Imaging.
[13] M. Scorsetti,et al. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study , 2017, Technology in cancer research & treatment.
[14] Wei-Chung Hsu,et al. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy , 2017, BMC Cancer.
[15] Mithat Gönen,et al. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. , 2011, International journal of radiation oncology, biology, physics.
[16] A. Grosu,et al. SBRT in pancreatic cancer: what is the therapeutic window? , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] Dwight E Heron,et al. Stereotactic Body Radiotherapy in the Treatment of Advanced Adenocarcinoma of the Pancreas , 2011, American journal of clinical oncology.
[18] Ravi Shridhar,et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. , 2013, International journal of radiation oncology, biology, physics.
[19] T. Desser,et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.
[20] Matthias Guckenberger,et al. Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.
[21] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[22] R. Hruban,et al. Pancreatic cancer , 2011, The Lancet.
[23] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[24] Ziding Feng,et al. Quantitative imaging to evaluate malignant potential of IPMNs , 2016, Oncotarget.
[25] Albert C. Koong,et al. Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.
[26] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[27] Ender Konukoglu,et al. Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[28] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[29] Daniel T Chang,et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas , 2009, Cancer.
[30] Geoffrey G. Zhang,et al. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms , 2016, Oncotarget.